|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...3940414243444546474849...6566» |
- ||||| Enrollment closed: Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 (clinicaltrials.gov) - Feb 11, 2014
P2/3, N=800, Active, not recruiting, Sponsor: Valneva Austria GmbH
Recruiting --> Active, not recruiting
- Trial termination: RESTORS: High Amylose Maize Starch for Treatment of Cholera (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=106, Terminated, Sponsor: PATH
Recruiting --> Active, not recruiting Recruiting --> Terminated; The study was closed early due to slow enrollment.
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial initiation date, Pneumococcal vaccines: Early Versus Delayed Pneumococcal Vaccination in HIV (clinicaltrials.gov) - Feb 10, 2014
P1/2, N=79, Completed, Sponsor: CIHR Canadian HIV Trials Network
Recruiting --> Terminated; The study was closed early due to slow enrollment. Initiation date: Apr 2003 --> Sep 2004
- Enrollment change: RESTORS: High Amylose Maize Starch for Treatment of Cholera (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=106, Terminated, Sponsor: PATH
Initiation date: Apr 2003 --> Sep 2004 N=150 --> 106
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: Early Versus Delayed Pneumococcal Vaccination in HIV (clinicaltrials.gov) - Feb 10, 2014
P1/2, N=79, Completed, Sponsor: CIHR Canadian HIV Trials Network
N=150 --> 106 Recruiting --> Completed
- ||| ceftaroline fosamil / Generic mfg.
Enrollment closed: Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Feb 9, 2014
P4, N=60, Active, not recruiting, Sponsor: Cerexa, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- Sirturo (bedaquiline) / J&J, Pharmstandard
Trial withdrawal: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (clinicaltrials.gov) - Feb 5, 2014
P3, N=0, Withdrawn, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- amoxicillin / Generic mfg.
Trial termination, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Withdrawn Not yet recruiting --> Terminated; Insufficient number of inclusion
- amoxicillin / Generic mfg.
Trial initiation date, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Terminated; Insufficient number of inclusion Initiation date: Feb 2010 --> Sep 2010
- Sirturo (bedaquiline) / J&J, Pharmstandard
Enrollment change: A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (clinicaltrials.gov) - Feb 5, 2014
P3, N=0, Withdrawn, Sponsor: Janssen Infectious Diseases BVBA
Initiation date: Feb 2010 --> Sep 2010 N=600 --> 0
- amoxicillin / Generic mfg.
Enrollment change, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
N=600 --> 0 N=646 --> 10
- ||||| Quinvaxem (diphtheria, Tetanus, whole-cell pertussis- HiB - HepB) / GSK
Enrollment closed: A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject (clinicaltrials.gov) - Feb 5, 2014
P3, N=400, Active, not recruiting, Sponsor: Crucell Holland BV
N=646 --> 10 Recruiting --> Active, not recruiting
- || Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Enrollment closed: Safety of MenACWY-CRM Vaccination in Adolescents (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=55429, Active, not recruiting, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes? (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=135, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- gepotidacin (GSK2140944) / GSK
Enrollment open: Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects (clinicaltrials.gov) - Feb 5, 2014
P1, N=46, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana (clinicaltrials.gov) - Feb 4, 2014
P4, N=2000, Completed, Sponsor: Centers for Disease Control and Prevention
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Vabomere (meropenem/vaborbactam) / Melinta Therap
Trial completion: Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects (clinicaltrials.gov) - Feb 3, 2014
P1, N=94, Completed, Sponsor: Rempex Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- Kineret (anakinra) / SOBI
Enrollment closed: Anakinra in Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 2, 2014
P2, N=20, Active, not recruiting, Sponsor: University of Athens
Recruiting --> Completed Recruiting --> Active, not recruiting
- Cubicin (daptomycin) / Merck (MSD)
Enrollment open: Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia (clinicaltrials.gov) - Feb 1, 2014
P2b, N=50, Recruiting, Sponsor: Singapore General Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Cubicin (daptomycin) / Merck (MSD)
Trial termination, Surgery: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty (clinicaltrials.gov) - Jan 30, 2014
P4, N=28, Terminated, Sponsor: Mountain Home Research & Education Corporation
Recruiting --> Terminated; The study is closed to accrual. Enrollment of new patients stopped at the request of CUBIST Pharmaceuticals due to slow rate of enrollment.
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change, Surgery: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty (clinicaltrials.gov) - Jan 30, 2014
P4, N=28, Terminated, Sponsor: Mountain Home Research & Education Corporation
Enrollment of new patients stopped at the request of CUBIST Pharmaceuticals due to slow rate of enrollment. N=100 --> 28
- | brilacidin (PMX-30063) / Innovation Pharma
New P2 trial: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections (clinicaltrials.gov) - Jan 30, 2014
P2, N=215, Enrolling by invitation, Sponsor: Cellceutix Pharmaceuticals
- New P2 trial: Efficacy of Propolis Varnish Against Oral Biofilm (clinicaltrials.gov) - Jan 30, 2014
P2, N=15, Not yet recruiting, Sponsor: Federal University of Minas Gerais
- Trial initiation date: Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos (clinicaltrials.gov) - Jan 30, 2014
P1, N=60, Not yet recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
N=100 --> 28 Initiation date: Sep 2013 --> Mar 2014
- ||| New P2/3 trial: Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion (clinicaltrials.gov) - Jan 29, 2014
P2/3, N=24, Recruiting, Sponsor: Atlantia Food Clinical Trials
- ||||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Trial completion: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age (clinicaltrials.gov) - Jan 29, 2014
P3, N=692, Completed, Sponsor: GlaxoSmithKline
Initiation date: Sep 2013 --> Mar 2014 Active, not recruiting --> Completed
- ||| Enrollment open: Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays (clinicaltrials.gov) - Jan 28, 2014
P=N/A, N=2100, Recruiting, Sponsor: Gen-Probe, Incorporated
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| ciprofloxacin oral / Generic mfg.
Trial completion: Ciprofloxacin BioThrax Co-Administration Study (clinicaltrials.gov) - Jan 27, 2014
P2, N=154, Completed, Sponsor: Emergent BioSolutions
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment open: Optimizing Clinical Outcomes in HIV-Infected Adults & Children (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=2816, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| TOBI Podhaler (tobramycin inhalation powder) / Viatris
Enrollment closed: Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis (clinicaltrials.gov) - Jan 26, 2014
P4, N=157, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- sodium phenylbutyrate / Generic mfg.
Enrollment closed: Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB) (clinicaltrials.gov) - Jan 25, 2014
P2, N=288, Active, not recruiting, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection (clinicaltrials.gov) - Jan 23, 2014
P4, N=200, Completed, Sponsor: American University of Beirut Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| gepotidacin (GSK2140944) / GSK
New P2 trial, Gram positive: Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Jan 23, 2014
P2, N=240, Recruiting, Sponsor: GlaxoSmithKline
- | gepotidacin (GSK2140944) / GSK
New P1 trial: Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects (clinicaltrials.gov) - Jan 23, 2014
P1, N=46, Recruiting, Sponsor: GlaxoSmithKline
- Clinical: Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study (clinicaltrials.gov) - Jan 22, 2014
P=N/A, N=190, Recruiting, Sponsor: University of Milan
- | bismuth subcitrate potassium/ metronidazole/tetracycline / Generic mfg.
New P4 trial: An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection (clinicaltrials.gov) - Jan 22, 2014
P4, N=100, Recruiting, Sponsor: American University of Beirut Medical Center
- atorvastatin / Generic mfg.
Enrollment closed: Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa (clinicaltrials.gov) - Jan 21, 2014
P4, N=32, Active, not recruiting, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- New P1 trial: A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers (clinicaltrials.gov) - Jan 21, 2014
P1, N=28, Completed, Sponsor: Oswaldo Cruz Foundation
- Trial completion: A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers (clinicaltrials.gov) - Jan 21, 2014
P1, N=28, Completed, Sponsor: Oswaldo Cruz Foundation
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- Trial initiation date: SOVS-CTG: Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=3500, Not yet recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Completed Initiation date: Oct 2013 --> Apr 2014
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Systems Biology of PNEUMOVAX®23 and PREVNAR 13® (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=88, Not yet recruiting, Sponsor: Emory University
Initiation date: Oct 2013 --> Apr 2014 N=66 --> 88
- Clinical: PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Regionshospitalet Viborg, Skive
- | Cubicin (daptomycin) / Merck (MSD)
Enrollment open, Monotherapy: Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia (clinicaltrials.gov) - Jan 20, 2014
P3, N=206, Recruiting, Sponsor: Miquel Pujol
N=66 --> 88 Not yet recruiting --> Recruiting
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion, IO biomarker: Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants (clinicaltrials.gov) - Jan 20, 2014
P3, N=1106, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | rifampicin / Generic mfg.
Clinical: Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9) (clinicaltrials.gov) - Jan 19, 2014
P3, N=822, Active, not recruiting, Sponsor: McGill University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=400, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- lansoprazole / Generic mfg., tetracycline / Generic mfg., esomeprazole / Generic mfg.
Trial termination: Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=30, Terminated, Sponsor: Chuncheon Sacred Heart Hospital
Not yet recruiting --> Completed Recruiting --> Terminated
- lansoprazole / Generic mfg., tetracycline / Generic mfg., esomeprazole / Generic mfg.
Enrollment change: Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=30, Terminated, Sponsor: Chuncheon Sacred Heart Hospital
Recruiting --> Terminated N=216 --> 30
- Enrollment change, Adherence: TBsurvey: Access to Care and Adherence Tuberculosis (TB) Survey (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=137, Completed, Sponsor: Azienda Ospedaliera San Gerardo di Monza
N=216 --> 30 N=200 --> 137
- tigecycline / Generic mfg., acetylcysteine solution / Generic mfg.
New P2/3 trial: Treatment of Hemodialysis Catheter-Related Bacteremia (clinicaltrials.gov) - Jan 16, 2014
P2/3, N=0, Not yet recruiting, Sponsor: University of California, San Diego